Frankfurt
,
Germany
6 - 9 February 2024
European Association for Haemophilia and Allied Disorders (EAHAD) 2024
Presentation schedule and materials
The congress symposium is no longer available
Wednesday, 07 February 2024
POSTER
Investigation of the suitability of the ROTEM assay to measure coagulation potential in blood from patients on concizumab prophylaxis
Hermann Eichler (Presenter) 1; Nora V. Butta2; Anne Riddell3; Cecilia Augustsson4; Marianne Kjalke5; Andrea P. Florencio5; Jan Astermark6; Victor Jiménez Yuste2; Pratima Chowdary3
POSTER
Surgical Procedures and Haemostatic Outcome in Patients with Haemophilia Receiving Concizumab Prophylaxis During the Phase 3 explorer7 and explorer8 Trials
Francisco-Jose Lopez-Jaime1 (Presenter); Chris Barnes2; Anthony K. C. Chan3; Silvia Linari4; Tadashi Matsushita5; Julien Bovet6; Jan Odgaard-Jensen6; Lone H. Poulsen7
POSTER
Treatment-related Humanistic Unmet Needs in Haemophilia B Without Inhibitors
Amy Shapiro1; Cléa Percier2; Thomas Porstmann2; Jennifer R Dusendang3; Allison P Wheeler4
POSTER
FVIII inhibitors can be accurately determined in haemophilia A plasma in the presence of Mim8
Karin Weldingh (Presenting author)1; William Pickering2; Mary Robinson2; Caroline Cogswell2; Mirella Ezban1
POSTER
Insights from people with haemophilia in France: Patient perspectives on the concizumab pen device
Sabine-Marie Castet1; (Presenter) Nicolas Béranger2; Lola Sepot-Boucherit2
POSTER
The efficacy, safety, and pharmacokinetics of N8-GP in previously treated Chinese patients with haemophilia A: results from the phase 3b pathfinder10 study
Jing Sun1; Yun Chen2; Wenqian Li3; Runhui Wu4; Feng’e Yang5; Xiaojing Zeng6; Zeping Zhou7; Xiaolei Bao8; Xiaoyan Li8; Marek Stanislaw Zak9; (Presenter) Renchi Yang10
Friday, 09 February 2024
ORAL PRESENTATION
Efficacy and safety of concizumab prophylaxis in haemophilia A or B with and without inhibitors: 56-week cut-off results of the phase 3 explorer7 and explorer8 studies
J Windyga (Presenting Author)1; S Apte2; J Astermark3; M Bruzelius4; G Castaman5; H Eichler6; K Hampton7; T Hansen8; P Knoebl9; A Lebreton10; S Linari5; CJ Lyu11; M Mathias12; A Rhode Høgh Nielsen8; L Hvitfeldt Poulsen13; S Šaulytė Trakymienė14; H Tran15; JJ Thaung Zaw8; R d’Oiron16; on behalf of the explorer7 and explorer8 investigators
ORAL PRESENTATION
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Mim8 in Patients with Haemophilia A: FRONTIER1 Extension
Pratima Chowdary (Presenting author)1; Steven R. Lentz2; Lidia Gil3; Francisco J. López-Jaime4; Jerzy Windyga5; Idlir Licaj6; Irina Matytsina7; Johnny Mahlangu8
Keywords